Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Argenica Therapeutics Ltd

AGN.AX ✗ NOT COMPLIANTFree checks used up today ☆ Track — members

ASX · Healthcare · Biotechnology & Medical Research ·

Australia Micro Cap Analyst: N/A

Last Close

$0.09

▼ -3.85%

Market Cap $11.21M · Vol 8.21K

Price charts are for members

Interactive price history from intraday to 5 years, on every stock and ETF.

See plans

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$11.21M

Micro Cap

Div Yield

0.00%

Annual dividend

EPS Growth

N/A

YoY

RSI (14)

40.00

Momentum

Beta

1.61

vs Market

52W High

$0.24

62.57% below

52W Low

$0.06

44.74% above

Volume

8.21K

Avg 66.89K

P/B

2.09

Price-to-book

ROE

N/A

Return on equity

Free Float

68.53%

Public shares

Shariah Compliance8 STANDARDS

✗ Argenica Therapeutics Ltd (AGN.AX) stock is currently not Shariah compliant

You’ve used your 10 free compliance checks today

Choose a plan

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives.Members see the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does AGN.AX pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-3.85%

-21.88%

+0.00%

-19.35%

YTD

-57.63%

-50.00%

-60.49%

-67.53%

Financials & Valuation

TTM · Annual

Total Revenue	$146.70K
Net Income	$-944,690.00
Revenue Growth (YoY)	-50.44%
Gross Margin	100.00%
Operating Margin	-3,160.90%
Net Profit Margin	-643.99%
ROE	N/A
ROA · ROIC	-15.55% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	58.16
P/B	2.09
P/FCF	N/A
EPS Growth	N/A
Outstanding Shares	128.46M

Technical Indicators

50-Day SMA	$0.12
200-Day SMA	$0.13
RSI (14)	40.00
Beta	1.61
52-Week High	$0.24
52-Week Low	$0.06

Volume Today	8.21K
Avg Daily Volume (30D)	66.89K
Relative Volume	0.12x
Volatility (10D)	73.55
Volatility (30D)	99.35
Free Float	68.53%

Analyst Consensus

N/A

Current Price $0.09

Mean Target N/A

52W Low$0.06 52W High$0.24

Current

Target

$0.06 $0.24

Current Analyst target

· 0 analysts

Identifiers

ExchangeASX

FIGIBBG010YS0TL2

ISINAU0000150328

CountryAustralia

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateN/A

TypeStocks

Instrument TypeFULLPAID Fully Paid Ordinary

Similar Halal Stocks

LONN.S Lonza Group AG +0.31% ONC BeOne Medicines AG -1.15% 068270.KS Celltrion, Inc. +0.45% MEDP Medpace Holdings, Inc. +1.31% ABVX Abivax SA -1.37%

Company Profile

Argenica Therapeutics Limited is an Australia-based clinical-stage biotechnology company. The Company develops neuroprotective therapeutics for patients following stroke and other acute neurological injuries. Its drug candidate, ARG-007, is designed to protect vulnerable brain tissue by reducing cell death and limiting secondary damage after an ischemic event. The Company has completed a Phase I clinical trial in healthy human volunteers to assess the safety and tolerability of a single dose of ARG-007. It has completed a Phase II clinical trial in ischaemic stroke patients, as well as continuing to generate preclinical data in other neurological conditions. The ARG-007 has a plurifunctional mechanism of action, affecting neuronal excitotoxicity, calcium influx and mitochondrial dysfunction, and reducing the activation of damaging proteolytic enzymes which enhances its neuroprotective potential and translational clinical effectiveness.